MCID: MYL006
MIFTS: 67

Myeloid Leukemia

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases

Aliases & Classifications for Myeloid Leukemia

MalaCards integrated aliases for Myeloid Leukemia:

Name: Myeloid Leukemia 12 53 29 55 15 73
Myeloid Granulocytic Leukemia 12
Non-Lymphocytic Leukemia 12
Leukemia Myelogenous 12
Leukemia, Myeloid 76

Classifications:



External Ids:

Disease Ontology 12 DOID:8692
ICD10 33 C92 C92.9 C92.90
ICD9CM 35 205 205.9
MeSH 44 D007951
NCIt 50 C3172
SNOMED-CT 68 37810007 94717009
UMLS 73 C0023470

Summaries for Myeloid Leukemia

Disease Ontology : 12 A leukemia that is located in myeloid tissue.

MalaCards based summary : Myeloid Leukemia, also known as myeloid granulocytic leukemia, is related to cytogenetically normal acute myeloid leukemia and core binding factor acute myeloid leukemia. An important gene associated with Myeloid Leukemia is MIR99AHG (Mir-99a-Let-7c Cluster Host Gene), and among its related pathways/superpathways are Pathways in cancer and Endometrial cancer. The drugs Bosulif and Gleevec have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Decreased substrate adherent cell growth and Decreased substrate adherent cell growth

Wikipedia : 76 Myeloid leukemia is a type of leukemia affecting myeloid... more...

Related Diseases for Myeloid Leukemia

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 626)
# Related Disease Score Top Affiliating Genes
1 cytogenetically normal acute myeloid leukemia 34.4 CEBPA FLT3 NPM1
2 core binding factor acute myeloid leukemia 34.3 CBFB CEBPA FLT3 KIT RUNX1
3 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 34.0 CBFB ETV6 FLT3 KIT MYH11 RUNX1
4 acute myeloid leukemia with t(8;21)(q22;q22) translocation 33.7 CEBPA FLT3 KIT RUNX1 RUNX1T1
5 leukemia, chronic myeloid 33.5 ABL1 ETV6 FLT3 GATA2 KIT MCL1
6 acute promyelocytic leukemia 33.5 CEBPA FLT3 MEIS1 NPM1 RUNX1
7 acute myeloblastic leukemia with maturation 33.5 FLT3 KIT NPM1
8 acute erythroid leukemia 33.3 CEBPA GATA2
9 leukemia, acute myeloid 33.1 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
10 leukemia 33.0 ABL1 CEBPA ETV6 FLT3 KIT MCL1
11 myeloid sarcoma 32.8 FLT3 KIT NPM1
12 myeloproliferative neoplasm 32.5 ABL1 KIT PTPN11
13 myelodysplastic syndrome 32.5 ABL1 CEBPA ETV6 FLT3 GATA2 KIT
14 acute myeloblastic leukemia without maturation 32.2 FLT3 NPM1
15 acute leukemia 31.2 CEBPA ETV6 FLT3 KIT RUNX1
16 lymphocytic leukemia 31.1 ETV6 MCL1 PTPN11 RUNX1
17 leukemia, acute lymphoblastic 31.1 ABL1 ETV6 FLT3 RUNX1
18 chronic myelomonocytic leukemia 31.0 ETV6 FLT3 KIT PTPN11 RUNX1
19 acute lymphocytic leukemia 30.6 ETV6 MCL1 RUNX1
20 lymphoid leukemia 30.6 ETV6 FLT3
21 chronic eosinophilic leukemia 30.2 ABL1 FLT3 KIT
22 aleukemic leukemia cutis 30.1 FLT3 MYH11 NPM1 RUNX1
23 8p11 myeloproliferative syndrome 29.9 FLT3 KIT RUNX1
24 childhood leukemia 29.8 ABL1 ETV6 PTPN11 RUNX1
25 precursor t-cell acute lymphoblastic leukemia 29.8 ABL1 ETV6 FLT3 NUP98
26 alk-positive anaplastic large cell lymphoma 29.8 MCL1 NPM1
27 platelet disorder, familial, with associated myeloid malignancy 29.8 ETV6 RUNX1
28 atypical chronic myeloid leukemia 12.6
29 familial acute myeloid leukemia with mutated cebpa 12.5
30 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) 12.5
31 subacute myeloid leukemia 12.3
32 philadelphia-negative chronic myeloid leukemia 12.3
33 therapy related acute myeloid leukemia and myelodysplastic syndrome 12.3
34 acute myeloid leukemia with minimal differentiation 12.3
35 acute myeloid leukemia with t(9;11)(p22;q23) 12.2
36 acute myeloid leukemia with t(6;9)(p23;q34) 12.2
37 acute myeloid leukemia with t(8;16)(p11;p13) translocation 12.2
38 cebpa-associated familial acute myeloid leukemia 12.2
39 acute myeloid leukemia with recurrent genetic anomaly 12.1
40 unclassified acute myeloid leukemia 12.1
41 acute myeloid leukemia and myelodysplastic syndromes related to radiation 12.1
42 megakaryoblastic acute myeloid leukemia with t(1;22)(p13;q13) 12.1
43 acute myeloid leukemia with npm1 somatic mutations 12.1
44 acute myeloid leukemia with 11q23 abnormalities 12.1
45 acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent 12.1
46 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor 12.1
47 megakaryocytic leukemia 12.0
48 pdgfrb-associated chronic eosinophilic leukemia 11.7
49 essential thrombocythemia 11.6
50 monocytic leukemia 11.6

Graphical network of the top 20 diseases related to Myeloid Leukemia:



Diseases related to Myeloid Leukemia

Symptoms & Phenotypes for Myeloid Leukemia

GenomeRNAi Phenotypes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased substrate adherent cell growth GR00193-A-1 9.63 KIT
2 Decreased substrate adherent cell growth GR00193-A-2 9.63 ABL1 KIT
3 Decreased substrate adherent cell growth GR00193-A-4 9.63 ABL1 FLT3 KIT
4 Increased shRNA abundance GR00327-A 9.35 CEBPA FLT3 MCL1 MYH11 PTPN11
5 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 9.1 GATA2 MCL1 MLF1 NUP98 RUNX1 RUNX1T1

MGI Mouse Phenotypes related to Myeloid Leukemia:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
2 cardiovascular system MP:0005385 10.33 ABL1 CBFB CEBPA ETV6 GATA2 KIT
3 growth/size/body region MP:0005378 10.32 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
4 hematopoietic system MP:0005397 10.27 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
5 embryo MP:0005380 10.25 ABL1 CBFB ETV6 GATA2 KIT MCL1
6 immune system MP:0005387 10.21 ABL1 CBFB CEBPA ETV6 FLT3 KIT
7 mortality/aging MP:0010768 10.2 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
8 endocrine/exocrine gland MP:0005379 10.19 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
9 integument MP:0010771 10.14 CBFB CEBPA ETV6 KIT MCL1 MECOM
10 digestive/alimentary MP:0005381 10.13 ABL1 CBFB CEBPA ETV6 KIT MYH11
11 liver/biliary system MP:0005370 10.02 ABL1 CBFB CEBPA GATA2 KIT MECOM
12 neoplasm MP:0002006 9.91 CBFB CEBPA ETV6 FLT3 KIT MECOM
13 no phenotypic analysis MP:0003012 9.7 CBFB CEBPA ETV6 FLT3 KIT PTPN11
14 normal MP:0002873 9.7 ABL1 CBFB CEBPA ETV6 GATA2 KIT
15 respiratory system MP:0005388 9.23 ABL1 CBFB CEBPA KIT MECOM MYH11

Drugs & Therapeutics for Myeloid Leukemia

FDA approved drugs:

(show all 8)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Bosulif 18 49 BOSUTINIB MONOHYDRATE Pfizer September 2012
2
Gleevec 18 49 IMATINIB MESYLATE Novartis May 2001
3
Iclusig 18 49 PONATINIB HYDROCHLORIDE Ariad Pharmaceuticals December 2012
4
Mylotarg 18 49 GEMTUZUMAB OZOGAMICIN Wyeth May 2000
5
Neupogen 18 49 FILGRASTIM Amgen Approval April 1998
6
Sprycel 18 49 DASATINIB Bristol-Myers Squibb June 2006
7
Synribo 18 49 OMACETAXINE MEPESUCCINATE Teva Pharmaceutical October 2012
8
Tasigna 18 49 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007

Drugs for Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 705)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
2
Idarubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
3
Vidarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 32326 21704
4
Fludarabine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
5
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 20830-81-3 30323
6
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65271-80-9 4212
7
Azacitidine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 320-67-2 9444
8
Decitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2353-33-5 451668
9
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
10
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 33419-42-0 36462
11 tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
12
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 53-03-2 5865
14
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
15
Topotecan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 123948-87-8, 119413-54-6 60700
16
Amsacrine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51264-14-3 2179
17
Aldesleukin Approved Phase 4,Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
18
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
19
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
20
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
21
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
22
Lenalidomide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 191732-72-6 216326
23
Histamine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 51-45-6, 75614-87-8 774
24
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
25
Micafungin Approved, Investigational Phase 4,Phase 2 235114-32-6 3081921 477468
26
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
27
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
28
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 1406-16-2
29
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2 67-97-0 5280795 6221
30
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2 50-14-6 5280793
31
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-86-4 3871
32
Aclarubicin Investigational Phase 4,Phase 2,Phase 1,Not Applicable 57576-44-0 451415
33 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
35 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
39 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
40 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
42 Protein Kinase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
43 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 220127-57-1 123596
44 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 tyrosine Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
47 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 3149)
# Name Status NCT ID Phase Drugs
1 Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia Unknown status NCT02277847 Phase 4 Idarubicin(8mg/m2) and cytosine arabinoside;Idarubicin(10mg/m2), cytosine arabinoside
2 AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy Unknown status NCT02024308 Phase 4 Fludarabine;Cytarabine
3 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
4 3 Anthracyclines, 2 Types of Consolidation With Different ARA-C Doses and Maintenance in Adult Acute Myeloid Leukemia Unknown status NCT01587430 Phase 4 high dose ARA-C;standard dose ARA-C
5 Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation Unknown status NCT01806116 Phase 4 decitabine
6 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
7 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
8 Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT Unknown status NCT02027064 Phase 4 Interferon-alpha
9 Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
10 Efficacy of G-CSF-Priming in Elderly AML Patients Unknown status NCT00199147 Phase 4 Cytarabine;Etoposide;Idarubicin;G-CSF;Fludarabine
11 Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia Unknown status NCT01997372 Phase 4 ATG
12 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
13 Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00488709 Phase 4 Topotecan;Fludarabine;Cytarabine
14 Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia Completed NCT01819792 Phase 4
15 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
16 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
17 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
18 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
19 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
20 LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) Completed NCT01041040 Phase 4 gemtuzumab
21 AML2003 - Standard-Therapy vs Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years Completed NCT00180102 Phase 4 Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone
22 Maintenance Therapy With Ceplene® (Histamine) and IL-2 on Immune Response and MRD in Acute Myeloid Leukemia Completed NCT01347996 Phase 4 histamine dihydrochloride and IL-2
23 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
24 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
25 Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
26 AML96 - Risk-Adapted and Randomized Postremission-Therapy for Adult Acute Myeloid Leukemia Patients Completed NCT00180115 Phase 4 Cytarabine Dosage
27 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
28 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
29 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
30 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
31 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
32 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
33 Therapy of Acute Myeloid Leukemia in Patients Over the Age of 60 : DA Versus Mitoxantrone With Intermittent AraC Completed NCT00180167 Phase 4 randomization between two established Chemotherapies
34 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
35 Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia Completed NCT00304447 Phase 4 Mylotarg
36 Oral Posaconazole in High Risk Patients With Gastrointestinal Dysfunction (Study P05115) Completed NCT00686543 Phase 4 Posaconazole
37 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
38 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
39 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
40 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
41 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
42 Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients Recruiting NCT03150134 Phase 4 Cyclosporine;routine reduction of immunosuppressive drugs(cyclosporine)
43 Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML Recruiting NCT02926586 Phase 4 Fludarabine;Cytarabine
44 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
45 Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients Recruiting NCT02267993 Phase 4 recombinant human thrombopoietin
46 Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections Recruiting NCT02805946 Phase 4 posaconazole
47 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
48 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
49 Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21) Active, not recruiting NCT03026842 Phase 4 Decitabine;Daunorubicin, Cytarabine;Mitoxantrone, Cytarabine;Aclacinomycin, Cytarabine
50 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib

Search NIH Clinical Center for Myeloid Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Myeloid Leukemia

Genetic tests related to Myeloid Leukemia:

# Genetic test Affiliating Genes
1 Myeloid Leukemia 29

Anatomical Context for Myeloid Leukemia

MalaCards organs/tissues related to Myeloid Leukemia:

41
Myeloid, Bone, Bone Marrow, T Cells, Nk Cells, Testes, Breast

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloid Leukemia:

19
Myeloid Tissue

Publications for Myeloid Leukemia

Articles related to Myeloid Leukemia:

(show top 50) (show all 8870)
# Title Authors Year
1
Hearing Status in Survivors of Childhood Acute Myeloid Leukemia Treated With Chemotherapy Only: A NOPHO-AML Study. ( 30550508 )
2019
2
TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. ( 30551433 )
2019
3
Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia. ( 30318867 )
2019
4
ADAMTS-13 activity reduction in plasma of acute myeloid leukemia predicts poor prognosis after bone marrow transplantation. ( 30322352 )
2019
5
Role of eIF3a in 4-amino-2-trifluoromethyl-phenyl retinate-induced cell differentiation in human chronic myeloid leukemia K562 cells. ( 30340049 )
2019
6
Comparison of conditioning regimens for autologous stem cell transplantation in children with acute myeloid leukemia: A nationwide retrospective study in Japan. ( 30270523 )
2019
7
FLT3 inhibitors in acute myeloid leukemia: Current and future. ( 30270754 )
2019
8
Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. ( 30105796 )
2019
9
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants. ( 30124384 )
2019
10
Stone RM, Manley PW, Larson RA, Capdeville R. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis. <i>Blood Adv</i>. 2017;2(4):444-453. ( 29618463 )
2018
11
High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. ( 29402726 )
2018
12
Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. ( 29468060 )
2018
13
Mutation profile and associated clinical features in Chinese patients with cytogenetically normal acute myeloid leukemia. ( 29573577 )
2018
14
Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation. ( 29330391 )
2018
15
Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia. ( 29431568 )
2018
16
Genetic Mutations in a Patient with Chronic Myeloid Leukemia Showing Blast Crisis 10 Years After Presentation. ( 29970518 )
2018
17
A regulatory circuitry between miR-193a/miR-600 and WT1 enhances leukemogenesis in acute myeloid leukemia. ( 29452230 )
2018
18
Monitoring of clonal evolution of double C-KIT exon 17 mutations by Droplet Digital PCR in patients with core-binding factor acute myeloid leukemia. ( 29705537 )
2018
19
PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia. ( 29964149 )
2018
20
Editorial Comment to Therapy-related acute myeloid leukemia and myelodysplastic syndrome among refractory germ cell tumor patients. ( 29869384 )
2018
21
MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. ( 29976747 )
2018
22
Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. ( 29168399 )
2018
23
High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia. ( 28836868 )
2018
24
Pilot Study on Mass Spectrometry-Based Analysis of the Proteome of CD34a8_CD123a8_ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. ( 29439554 )
2018
25
Patient-reported outcomes in acute myeloid leukemia: Where are we now? ( 28888621 )
2018
26
A case of chronic eosinophilic leukemia with secondary transformation to acute myeloid leukemia. ( 29892549 )
2018
27
Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia. ( 29154208 )
2018
28
Regulation of Expression of CEBP Genes by Variably Expressed Vitamin D Receptor and Retinoic Acid Receptor I+ in Human Acute Myeloid Leukemia Cell Lines. ( 29966306 )
2018
29
Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia. ( 28540755 )
2018
30
Up-regulation of regulatory T cells, CD200 and TIM3 expression in cytogenetically normal acute myeloid leukemia. ( 29843224 )
2018
31
Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. ( 29247780 )
2018
32
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia. ( 28646564 )
2018
33
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia. ( 28776669 )
2018
34
Q482H mutation of procaspase-8 in acute myeloid leukemia abolishes caspase-8-mediated apoptosis by impairing procaspase-8 dimerization. ( 29191655 )
2018
35
Breakthrough invasive aspergillosis and diagnostic accuracy of serum galactomannan enzyme immune assay during acute myeloid leukemia induction chemotherapy with posaconazole prophylaxis. ( 29928481 )
2018
36
Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group. ( 29151104 )
2018
37
Successful Treatment of Cytogenetically Normal Acute Myeloid Leukemia With Ten-Eleven Translocation 2-Isocitrate Dehydrogenase 2 and Additional Sex Comb-like 1-Nucleophosmin Co-mutations by HLA Haploidentical Stem Cell Transplantation: A Case Report and Literature Review. ( 29661468 )
2018
38
Outcome of patient with high-risk chronic myelomonocytic leukemia, treated with decitabine prior to transformation to acute myeloid leukemia: A case report. ( 29731877 )
2018
39
Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). ( 29978286 )
2018
40
Acute Progressive Visual Loss in a Case of Acute Myeloid Leukemia: Challenges in the Utility of Molecular Tests in Early Diagnose of Cytomegalovirus Retinitis. ( 29560000 )
2018
41
Therapy-related Acute Myeloid Leukemia After the Treatment of Primary Solid Cancer in Children: A Single-center Experience. ( 29200163 )
2018
42
Lower expression of bone marrow miR-122 is an independent risk factor for overall survival in cytogenetically normal acute myeloid leukemia. ( 29627222 )
2018
43
Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia. ( 29980537 )
2018
44
A typical atypical chronic myeloid leukemia. ( 29744086 )
2018
45
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+). ( 28838276 )
2018
46
Multiple small bowel perforations due to invasive aspergillosis in a patient with acute myeloid leukemia: case report and a systematic review of the literature. ( 29357049 )
2018
47
Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1. ( 29321554 )
2018
48
Downregulated miR-217A expression predicts a poor outcome in acuteA myeloid leukemia. ( 29439315 )
2018
49
<i>NPM1</i> Mutation Analysis in Acute Myeloid Leukemia: Comparison of Three Techniques - Sanger Sequencing, Pyrosequencing, and Real-Time Polymerase Chain Reaction. ( 29129825 )
2018
50
Initial therapy for acute myeloid leukemia in older patients: principles of care. ( 28573900 )
2018

Variations for Myeloid Leukemia

Expression for Myeloid Leukemia

Search GEO for disease gene expression data for Myeloid Leukemia.

Pathways for Myeloid Leukemia

GO Terms for Myeloid Leukemia

Cellular components related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.9 ABL1 CBFB CEBPA GATA2 MCL1 MECOM
2 protein-containing complex GO:0032991 9.65 ABL1 FLT3 GATA2 NPM1 PTPN11
3 nucleus GO:0005634 9.53 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
4 core-binding factor complex GO:0016513 8.96 CBFB RUNX1

Biological processes related to Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.96 ABL1 CEBPA ETV6 GATA2 MECOM MEIS1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 ABL1 FLT3 KIT PTPN11
3 cytokine-mediated signaling pathway GO:0019221 9.85 CEBPA FLT3 KIT MCL1 PTPN11
4 cell maturation GO:0048469 9.65 CBFB CEBPA GATA2
5 negative regulation of myeloid cell differentiation GO:0045638 9.63 GATA2 MEIS1
6 cell fate determination GO:0001709 9.62 GATA2 MCL1
7 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.62 CBFB RUNX1
8 regulation of keratinocyte differentiation GO:0045616 9.61 CBFB RUNX1
9 regulation of regulatory T cell differentiation GO:0045589 9.61 CBFB RUNX1
10 negative regulation of programmed cell death GO:0043069 9.6 KIT MECOM
11 regulation of bicellular tight junction assembly GO:2000810 9.59 CBFB RUNX1
12 regulation of B cell receptor signaling pathway GO:0050855 9.58 CBFB RUNX1
13 definitive hemopoiesis GO:0060216 9.58 CBFB GATA2 MEIS1
14 regulation of myeloid cell differentiation GO:0045637 9.57 CBFB RUNX1
15 regulation of response to DNA damage stimulus GO:2001020 9.56 ABL1 MCL1
16 Bergmann glial cell differentiation GO:0060020 9.55 ABL1 PTPN11
17 regulation of cytokine-mediated signaling pathway GO:0001959 9.54 CBFB RUNX1
18 megakaryocyte development GO:0035855 9.54 KIT MEIS1 PTPN11
19 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.51 CBFB RUNX1
20 hematopoietic stem cell proliferation GO:0071425 9.5 ETV6 MECOM RUNX1
21 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.49 CBFB RUNX1
22 hemopoiesis GO:0030097 9.35 FLT3 GATA2 KIT MEIS1 RUNX1
23 myeloid progenitor cell differentiation GO:0002318 9.33 FLT3 KIT MLF1
24 regulation of hematopoietic stem cell differentiation GO:1902036 8.92 ABL1 CBFB GATA2 RUNX1
25 positive regulation of transcription by RNA polymerase II GO:0045944 10.07 CBFB CEBPA ETV6 GATA2 MEIS1 NPM1
26 transcription by RNA polymerase II GO:0006366 10.03 CBFB CEBPA ETV6 MEIS1 RUNX1
27 cell differentiation GO:0030154 10.03 ABL1 ETV6 FLT3 GATA2 KIT MCL1

Molecular functions related to Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.98 CBFB CEBPA ETV6 GATA2 MECOM MEIS1
2 protein binding GO:0005515 9.91 ABL1 CBFB CEBPA ETV6 FLT3 GATA2
3 sequence-specific DNA binding GO:0043565 9.85 CBFB CEBPA ETV6 GATA2 MEIS1
4 proximal promoter DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001077 9.71 CEBPA ETV6 GATA2 MEIS1
5 DNA-binding transcription factor activity GO:0003700 9.7 CBFB CEBPA ETV6 GATA2 MECOM RUNX1
6 transcription coactivator activity GO:0003713 9.67 CBFB CEBPA NPM1 NUP98
7 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.65 CEBPA ETV6 GATA2 MEIS1 RUNX1
8 protein domain specific binding GO:0019904 9.62 ABL1 ETV6 MLF1 PTPN11
9 DNA binding GO:0003677 9.36 ABL1 CBFB CEBPA ETV6 GATA2 MECOM

Sources for Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....